Payment overview · 2025
General Payments
$315.34
11 reported records · 3 companies
Healthcare provider profile · identity verified
Silva Karchikian, MD
Allopathic & Osteopathic Physicians|General Practice · GLENDALE, CA · NPI 1922010388
Verified facts
What the public records show
CMS Open Payments records show Silva Karchikian, MD received $315.34 in general payments during 2025 across 11 reported records.
Amgen Inc. accounted for 86.2% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 4 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Linzess.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ARMOUR THYROID as an associated drug or biological on 50 records involving 11 distinct recipient NPIs. Public Medicare Part D data also shows 26 claims for Armour Thyroid by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported CREON as an associated drug or biological on 91561 records involving 20616 distinct recipient NPIs. Public Medicare Part D data also shows 72 claims for Creon by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 215 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 38 claims for Synthroid by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 349 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 55 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 116 claims for Trulicity by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Amgen Inc. | Unresolved — no canonical attribution shown | $271.92 | 86.2% | 9 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $26.72 | 8.5% | 1 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $16.70 | 5.3% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $315.34 | 11 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $271.92 | 9 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $53.89 | 3 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $26.72 | 1 | 2025 |
Source payment records
|
|||||
| LINZESS Normalized: linzess |
Drug | ABBVIE INC. | $16.70 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| LINZESS linzess |
2025 | Linzess | 2024 | 215 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | ARMOUR THYROID open payments reported associated product |
CMS Open Payments — General Payments 50 supporting records · 11 recipient NPIs · example record 1201517088 |
Armour Thyroid · 2024 Exact normalized brand match · 1 Part D row |
26 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | CREON open payments reported associated product |
CMS Open Payments — General Payments 91561 supporting records · 20616 recipient NPIs · example record 1201352608 |
Creon · 2024 Exact normalized brand match · 1 Part D row |
72 | 14 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
215 | 29 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
38 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
349 | 39 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
55 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
116 | 19 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 1077 | 135 |
| Amlodipine Besylate | Amlodipine Besylate | 897 | 106 |
| Metformin Hcl | Metformin Hcl | 782 | 95 |
| Levothyroxine Sodium | Levothyroxine Sodium | 761 | 78 |
| Gabapentin | Gabapentin | 692 | 81 |
| Omeprazole | Omeprazole | 637 | 93 |
| Ibuprofen | Ibuprofen | 573 | 80 |
| Meclizine Hcl | Meclizine Hcl | 570 | 69 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 501 | 56 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 461 | 65 |
| Losartan Potassium | Losartan Potassium | 457 | 59 |
| Clonidine Hcl | Clonidine Hcl | 438 | 54 |
| Escitalopram Oxalate | Escitalopram Oxalate | 356 | 48 |
| Jardiance | Empagliflozin | 349 | 39 |
| Alendronate Sodium | Alendronate Sodium | 345 | 39 |
| Simvastatin | Simvastatin | 345 | 36 |
| Lisinopril | Lisinopril | 332 | 51 |
| Vascepa | Icosapent Ethyl | 311 | 49 |
| Meloxicam | Meloxicam | 299 | 38 |
| Metoprolol Succinate | Metoprolol Succinate | 299 | 43 |
| Atenolol | Atenolol | 276 | 34 |
| Furosemide | Furosemide | 270 | 37 |
| Tamsulosin Hcl | Tamsulosin Hcl | 257 | 35 |
| Hydrochlorothiazide | Hydrochlorothiazide | 243 | 34 |
| Diclofenac Sodium | Diclofenac Sodium | 242 | 49 |
| Hydralazine Hcl | Hydralazine Hcl | 240 | 29 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 230 | 37 |
| Metoprolol Tartrate | Metoprolol Tartrate | 218 | 25 |
| Ozempic | Semaglutide | 218 | 33 |
| Donepezil Hcl | Donepezil Hcl | 215 | 25 |
| Linzess | Linaclotide | 215 | 29 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 215 | 36 |
| Icosapent Ethyl | Icosapent Ethyl | 210 | 44 |
| Clopidogrel | Clopidogrel Bisulfate | 183 | 27 |
| Allopurinol | Allopurinol | 182 | 20 |
| Dexlansoprazole Dr | Dexlansoprazole | 181 | 27 |
| Carvedilol | Carvedilol | 179 | 24 |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 162 | 17 |
| Glipizide | Glipizide | 159 | 21 |
| Sertraline Hcl | Sertraline Hcl | 155 | 20 |
| Alcohol Prep Pads | Alcohol Antiseptic Pads | 153 | 30 |
| Januvia | Sitagliptin Phosphate | 153 | 16 |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 148 | 16 |
| Potassium Chloride | Potassium Chloride | 135 | 18 |
| Glimepiride | Glimepiride | 134 | 13 |
| Enalapril Maleate | Enalapril Maleate | 132 | 15 |
| Ezetimibe | Ezetimibe | 131 | 15 |
| Azithromycin | Azithromycin | 125 | 93 |
| Alprazolam | Alprazolam | 124 | 31 |
| Trazodone Hcl | Trazodone Hcl | 123 | 15 |
| Trulicity | Dulaglutide | 116 | 19 |
| Fluticasone Propionate | Fluticasone Propionate | 115 | 22 |
| Pravastatin Sodium | Pravastatin Sodium | 112 | 13 |
| Memantine Hcl | Memantine Hcl | 108 | 12 |
| Propranolol Hcl | Propranolol Hcl | 108 | 11 |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 105 | 18 |
| Tramadol Hcl | Tramadol Hcl | 105 | 22 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 103 | 13 |
| Janumet | Sitagliptin Phos/Metformin Hcl | 100 | 13 |
| Benazepril Hcl | Benazepril Hcl | 94 | 12 |
| Colchicine | Colchicine | 94 | suppressed |
| Celecoxib | Celecoxib | 93 | 16 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 92 | 14 |
| Famotidine | Famotidine | 90 | 13 |
| Pantoprazole Sodium | Pantoprazole Sodium | 89 | 16 |
| Ventolin Hfa | Albuterol Sulfate | 86 | 17 |
| Ketoconazole | Ketoconazole | 84 | 15 |
| Montelukast Sodium | Montelukast Sodium | 84 | suppressed |
| Naproxen | Naproxen | 84 | 11 |
| Eliquis | Apixaban | 82 | 14 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 82 | 12 |
| Nifedipine Er | Nifedipine | 81 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 80 | 13 |
| Citalopram Hbr | Citalopram Hydrobromide | 79 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 75 | 14 |
| Valsartan | Valsartan | 75 | suppressed |
| Creon | Lipase/Protease/Amylase | 72 | 14 |
| Hydrocortisone | Hydrocortisone | 72 | 20 |
| Lorazepam | Lorazepam | 72 | 14 |
| Clonidine | Clonidine | 70 | 12 |
| Nitroglycerin | Nitroglycerin | 69 | 14 |
| Baclofen | Baclofen | 64 | suppressed |
| Trintellix | Vortioxetine Hydrobromide | 63 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 62 | suppressed |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 60 | 11 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 60 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 60 | suppressed |
| Clotrimazole | Clotrimazole | 58 | 14 |
| Zenpep | Lipase/Protease/Amylase | 58 | suppressed |
| Methimazole | Methimazole | 57 | suppressed |
| Fenofibrate | Fenofibrate,micronized | 55 | suppressed |
| Mounjaro | Tirzepatide | 55 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 50 | suppressed |
| Pregabalin | Pregabalin | 48 | suppressed |
| Mirtazapine | Mirtazapine | 46 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 45 | suppressed |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 44 | suppressed |
| Finasteride | Finasteride | 44 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 43 | suppressed |
| Pitavastatin Calcium | Pitavastatin Calcium | 42 | suppressed |
| Mupirocin | Mupirocin | 41 | suppressed |
| Betamethasone Dipropionate | Betamethasone Dipropionate | 40 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 39 | suppressed |
| Synthroid | Levothyroxine Sodium | 38 | suppressed |
| Diflorasone Diacetate | Diflorasone Diacetate | 37 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 36 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 35 | suppressed |
| Easy Touch Alcohol Prep Pads | Alcohol Antiseptic Pads | 35 | suppressed |
| Metformin Er Gastric | Metformin Hcl | 35 | suppressed |
| Omeprazole-Sodium Bicarbonate | Omeprazole/Sodium Bicarbonate | 34 | suppressed |
| Procto-Med Hc | Hydrocortisone | 34 | suppressed |
| Silver Sulfadiazine | Silver Sulfadiazine | 34 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 32 | suppressed |
| Ondansetron Odt | Ondansetron | 32 | suppressed |
| Spironolactone | Spironolactone | 32 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 32 | 11 |
| Lovastatin | Lovastatin | 31 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 30 | suppressed |
| Alcohol Swabs | Alcohol Antiseptic Pads | 29 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 29 | suppressed |
| Myrbetriq | Mirabegron | 29 | suppressed |
| Jentadueto | Linagliptin/Metformin Hcl | 28 | suppressed |
| Repatha Sureclick | Evolocumab | 28 | suppressed |
| Glipizide Er | Glipizide | 27 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 27 | suppressed |
| Tradjenta | Linagliptin | 27 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 27 | suppressed |
| Armour Thyroid | Thyroid,pork | 26 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 26 | suppressed |
| Nexium | Esomeprazole Magnesium | 26 | suppressed |
| Sotalol | Sotalol Hcl | 26 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 25 | suppressed |
| Fluocinonide | Fluocinonide | 25 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 25 | suppressed |
| Ranolazine Er | Ranolazine | 25 | suppressed |
| Risperidone | Risperidone | 25 | suppressed |
| Ibu | Ibuprofen | 24 | suppressed |
| Multaq | Dronedarone Hcl | 23 | suppressed |
| Entresto | Sacubitril/Valsartan | 22 | suppressed |
| Levofloxacin | Levofloxacin | 22 | 19 |
| Lofena | Diclofenac Potassium | 22 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 22 | suppressed |
| Ultra-Fine Nano Pen Needle | Pen Needle, Diabetic | 22 | suppressed |
| Clonazepam | Clonazepam | 21 | suppressed |
| Dexilant | Dexlansoprazole | 21 | suppressed |
| Estradiol | Estradiol | 21 | suppressed |
| Hydrocortisone Butyrate | Hydrocortisone Butyrate | 20 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 20 | suppressed |
| Novolog Flexpen | Insulin Aspart | 20 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 20 | suppressed |
| Amoxicillin | Amoxicillin | 19 | 18 |
| Clobetasol Propionate | Clobetasol Propionate | 19 | suppressed |
| Novofine Autocover | Pen Needle, Diabetic, Safety | 19 | suppressed |
| Benazepril-Hydrochlorothiazide | Benazepril/Hydrochlorothiazide | 18 | suppressed |
| Betamethasone Diprop Augmented | Betamethasone/Propylene Glyc | 18 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 18 | suppressed |
| Naproxen-Esomeprazole Mag | Naproxen/Esomeprazole Mag | 18 | suppressed |
| Prednisone | Prednisone | 18 | 11 |
| Sulindac | Sulindac | 18 | suppressed |
| Telmisartan | Telmisartan | 18 | suppressed |
| Gemtesa | Vibegron | 17 | suppressed |
| Digoxin | Digoxin | 16 | suppressed |
| Lansoprazole | Lansoprazole | 16 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 16 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 16 | 14 |
| Ramipril | Ramipril | 16 | suppressed |
| Diltiazem Hcl | Diltiazem Hcl | 15 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 15 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 15 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 15 | suppressed |
| Cilostazol | Cilostazol | 14 | suppressed |
| Comfort Ez Pen Needle | Pen Needle, Diabetic | 14 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 14 | suppressed |
| Ezetimibe-Simvastatin | Ezetimibe/Simvastatin | 14 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 14 | suppressed |
| Megestrol Acetate | Megestrol Acetate | 14 | suppressed |
| Metronidazole | Metronidazole | 14 | suppressed |
| Niacin Er | Niacin | 14 | suppressed |
| Rybelsus | Semaglutide | 14 | suppressed |
| Aliskiren | Aliskiren Hemifumarate | 13 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 13 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 13 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 13 | suppressed |
| Carbidopa-Levodopa Er | Carbidopa/Levodopa | 13 | suppressed |
| Chlorthalidone | Chlorthalidone | 13 | suppressed |
| Clindamycin Phosphate | Clindamycin Phosphate | 13 | suppressed |
| Febuxostat | Febuxostat | 13 | suppressed |
| Fosinopril Sodium | Fosinopril Sodium | 13 | suppressed |
| Levetiracetam | Levetiracetam | 13 | suppressed |
| Premarin | Estrogens, Conjugated | 13 | suppressed |
| Synjardy | Empagliflozin/Metformin Hcl | 13 | suppressed |
| Acetazolamide | Acetazolamide | 12 | suppressed |
| Brilinta | Ticagrelor | 12 | suppressed |
| Diltiazem 12hr Er | Diltiazem Hcl | 12 | suppressed |
| Duloxetine Hcl | Duloxetine Hcl | 12 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 12 | suppressed |
| Humulin 70-30 | Insulin Nph Hum/Reg Insulin Hm | 12 | suppressed |
| Irbesartan | Irbesartan | 12 | suppressed |
| Letrozole | Letrozole | 12 | suppressed |
| Loperamide | Loperamide Hcl | 12 | suppressed |
| Naproxen Sodium | Naproxen Sodium | 12 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 12 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 12 | suppressed |
| Ciclopirox | Ciclopirox | 11 | suppressed |
| Dihydroergotamine Mesylate | Dihydroergotamine Mesylate | 11 | suppressed |
| Neomycin-Polymyxin-Dexameth | Neomycin/Polymyxin B/Dexametha | 11 | suppressed |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $315.34 · 11 records | Amgen Inc. | LINZESS, OTEZLA, REPATHA, ZEPBOUND | 7 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Linzess play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error